title: [Hepatitis C virus antibodies in patients following blood transfusion and kidney transplantation].
abstract: The prevalence of anti-HCV in patients after kidney transplantation was tested by HCV-Antibody-ELISA (Ortho Diagnostics). In addition, reactive samples were tested by HCV-EIA (Abbott Laboratories), neutralization, anti-HBc (Corzyme, Abbott) and by HBs-Ag (Auszyme, Abbott). 27 of 271 patients (10%) were anti-HCV positive. Receiving more than one kidney graft (TPL) or the transfusion of more than four blood units (BU) increases the risk of HCV infection four times (OR: 4.1; p less than 0.01) or 2.5 times (OR: 2.5; p less than 0.05), respectively, compared with one TPL or less than 4 BU. Receiving more than one kidney graft and transfusion of more than four BU raises the risk of HCV infection 6.8 times. 52% of anti-HCV positive patients were anti-HBc positive, 48% were anti-HBc negative as well as HBs-Ag negative.
authors.affiliation: Institut für Immunologie und Serologie, Universität Heidelberg.
authors.forename: P
authors.initials: P
authors.lastname: Baur
authors.forename: V
authors.initials: V
authors.lastname: Daniel
authors.forename: S
authors.initials: S
authors.lastname: Pomer
authors.forename: H
authors.initials: H
authors.lastname: Scheurlen
authors.forename: G
authors.initials: G
authors.lastname: Opelz
authors.forename: D
authors.initials: D
authors.lastname: Roelcke
mesh_terms: D001803:Blood Transfusion; D003430:Cross-Sectional Studies; D005858:Germany / Q000453:epidemiology; D016174:Hepacivirus / Q000276:immunology*; D006508:Hepatitis Antibodies / Q000032:analysis*; D006526:Hepatitis C / Q000175:diagnosis / Q000453:epidemiology* / Q000276:immunology; D006801:Humans; D015994:Incidence; D016030:Kidney Transplantation / Q000276:immunology*; D016017:Odds Ratio; D011183:Postoperative Complications / Q000175:diagnosis / Q000453:epidemiology* / Q000276:immunology; D012044:Regression Analysis; D012307:Risk Factors
chemical_list: D006508:Hepatitis Antibodies
vernacular_title: Hepatitis C-Virus (HCV) Antikörper bei Patienten nach Bluttransfusionen und Nierentransplantation.